Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 8 studies | 26% ± 6% | |
fibroblast | 8 studies | 18% ± 4% | |
smooth muscle cell | 7 studies | 19% ± 3% | |
pericyte | 6 studies | 20% ± 4% | |
oligodendrocyte | 5 studies | 24% ± 7% | |
epithelial cell | 4 studies | 33% ± 12% | |
GABAergic neuron | 4 studies | 34% ± 8% | |
astrocyte | 4 studies | 27% ± 7% | |
glutamatergic neuron | 4 studies | 41% ± 15% | |
classical monocyte | 3 studies | 21% ± 4% | |
oligodendrocyte precursor cell | 3 studies | 29% ± 7% | |
macrophage | 3 studies | 18% ± 3% | |
neuron | 3 studies | 25% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2741.64 | 1445 / 1445 | 100% | 24.18 | 183 / 183 |
ovary | 100% | 3383.86 | 180 / 180 | 100% | 19.90 | 429 / 430 |
lung | 100% | 2804.88 | 577 / 578 | 100% | 18.22 | 1153 / 1155 |
breast | 100% | 4350.23 | 459 / 459 | 100% | 28.83 | 1113 / 1118 |
prostate | 100% | 2704.76 | 244 / 245 | 100% | 27.12 | 501 / 502 |
thymus | 100% | 4316.45 | 653 / 653 | 99% | 28.40 | 601 / 605 |
brain | 99% | 2145.53 | 2620 / 2642 | 100% | 22.23 | 705 / 705 |
bladder | 100% | 2820.00 | 21 / 21 | 99% | 16.30 | 497 / 504 |
stomach | 100% | 1846.61 | 358 / 359 | 99% | 19.01 | 282 / 286 |
uterus | 100% | 3807.68 | 170 / 170 | 98% | 17.22 | 449 / 459 |
intestine | 100% | 2844.77 | 966 / 966 | 98% | 18.22 | 514 / 527 |
kidney | 100% | 1992.44 | 89 / 89 | 97% | 21.72 | 873 / 901 |
adrenal gland | 99% | 2146.40 | 256 / 258 | 93% | 13.71 | 215 / 230 |
pancreas | 91% | 1063.72 | 298 / 328 | 99% | 17.67 | 176 / 178 |
skin | 100% | 3061.69 | 1809 / 1809 | 87% | 13.37 | 409 / 472 |
liver | 98% | 1271.41 | 222 / 226 | 84% | 8.04 | 343 / 406 |
blood vessel | 100% | 6013.95 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 16.02 | 29 / 29 |
spleen | 100% | 2488.78 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 17.22 | 45 / 45 |
adipose | 100% | 4924.62 | 1203 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 2073.91 | 799 / 803 | 0% | 0 | 0 / 0 |
heart | 96% | 1664.80 | 826 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 68% | 1227.08 | 630 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 48% | 3.86 | 38 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0043153 | Biological process | entrainment of circadian clock by photoperiod |
GO_0016567 | Biological process | protein ubiquitination |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0048511 | Biological process | rhythmic process |
GO_0031648 | Biological process | protein destabilization |
GO_0042752 | Biological process | regulation of circadian rhythm |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0016604 | Cellular component | nuclear body |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXL3 |
Protein name | F-box and leucine rich repeat protein 3 F-box/LRR-repeat protein 3 (F-box and leucine-rich repeat protein 3A) (F-box/LRR-repeat protein 3A) |
Synonyms | FBL3A FBXL3A |
Description | FUNCTION: Substrate-recognition component of the SCF(FBXL3) E3 ubiquitin ligase complex involved in circadian rhythm function. Plays a key role in the maintenance of both the speed and the robustness of the circadian clock oscillation . The SCF(FBXL3) complex mainly acts in the nucleus and mediates ubiquitination and subsequent degradation of CRY1 and CRY2 . Activity of the SCF(FBXL3) complex is counteracted by the SCF(FBXL21) complex . . |
Accessions | Q9UKT7 C9J0Y7 ENST00000417323.1 ENST00000355619.10 |